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Abstract: A strong mechanistic link between the regulation of iron homeostasis and oxygen sensing
is evident in the lung, where both systems must be properly controlled to maintain lung function.
Imbalances in pulmonary iron homeostasis are frequently associated with respiratory diseases,
such as chronic obstructive pulmonary disease and with lung cancer. However, the underlying
mechanisms causing alterations in iron levels and the involvement of iron in the development of lung
disorders are incompletely understood. Here, we review current knowledge about the regulation
of pulmonary iron homeostasis, its functional importance, and the link between dysregulated iron
levels and lung diseases. Gaining greater knowledge on how iron contributes to the pathogenesis of
these diseases holds promise for future iron-related therapeutic strategies.
Keywords: iron homeostasis; lung diseases; oxygen sensing; hypoxia
1. Introduction
Every cell requires sufficient oxygen to satisfy its demand for oxidative metabolism. Red blood
cells (RBCs) are in the center of this process by transporting oxygen from the lungs to every tissue.
Efficient oxygen transported by RBCs relies on the presence of hemoglobin, a protein containing four
heme groups that have the ability to bind oxygen through their central iron atom. To sustain adequate
erythropoiesis, approximately 20–25 mg of iron are required daily [1]. In addition to hemoglobin
synthesis, iron is necessary for other fundamental metabolic processes, including DNA synthesis
and repair, transcription, and energy production in the mitochondria [2]. Therefore, iron is essential
for the biology of almost all organisms. Insufficient intracellular iron levels impair the activity of
iron-containing proteins, ultimately compromising cell function and viability. Iron’s critical role is
explained by its potential to fluctuate between oxidation states, mainly between divalent ferrous (Fe2+)
and trivalent ferric (Fe3+) iron [3]. However, this chemical property as a transition metal makes free
iron very reactive and potentially toxic. Iron catalyzes the production of reactive oxygen species (ROS)
via the Fenton and Haber-Weiss reactions [4]. Exposure to these highly reactive radicals damages
lipids, nucleic acids, and proteins, causing cell and thus tissue damage. To counteract its chemical
reactivity, iron in the body is mainly bound to prosthetic groups, such as heme in hemoglobin or
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myoglobin, and to proteins, such as the plasma iron transport protein transferrin or the intracellular
iron storage protein ferritin. This dual role of iron makes it essential to tightly control iron homeostasis
to meet the cellular and systemic metabolic needs while preventing detrimental iron overload. In other
words, like oxygen, iron represents a double-edge sword and thus requires exact regulation.
Adequate iron supply and homeostasis depends on systemic plasma availability. Under balanced
conditions, only 1–2 mg of iron from dietary sources are absorbed daily by duodenal enterocytes to
compensate for small iron losses (e.g., blood loss and desquamation of epithelial surfaces) or increased
demand (e.g., pregnancy or hypoxic exposure). Most of the iron required to sustain the body’s
metabolic needs is provided by reticuloendothelial macrophages that recycle iron from senescent
RBCs [5]. Hepatocytes in the liver are specialized for iron storage, acting as an iron buffer system. Since
nature has not come up with a regulated way to eliminate iron from the organism, the coordination of
iron fluxes from tissues to circulation is essential to maintain plasma iron levels within a physiological
range (10–30 µM) [6]. Plasma iron levels are mainly controlled by the hepcidin/ferroportin regulatory
system (Figure 1) [1]. The hepatic hormone hepcidin is secreted in conditions of high systemic
iron levels and binds to the only known cellular iron exporter ferroportin (FPN), thereby inducing its
ubiquitination, endocytosis, and lysosomal degradation [7,8]. This causes a decrease in iron export from
FPN expressing cell-types, such as duodenal enterocytes and iron-recycling macrophages, ultimately
leading to a decrease in plasma iron levels.
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Figure 1. The above image represents systemic iron homeostasis. Dietary iron absorption occurs at
the brush-border membrane of duodenal enterocytes. Ferric iron (Fe3+) is reduced to ferrous iron
(Fe2+) by duodenal cytochrome B (DCYTB) and is transported across the membrane via divalent metal
transporter 1 (DMT1). The export of iron through the basolateral membrane of enterocytes occurs
via ferroportin (FPN) and is coupled to the reoxidation of Fe2+ to Fe3+, a process that is catalyzed by
hephaestin. Ferric iron circulates in the blood bound to transferrin (Tf-Fe2). Transferrin-bound iron can
be taken up via transferrin receptor 1 (TfR1) by every cell type in the organism, including hepatocytes
that store high amounts of iron in ferritin. Hepatocytes can also take up non-transferrin-bound iron
(NTBI) via ZRT/IRT-like protein (ZIP14). When required, iron can be exported from hepatocytes
via FPN back to circulation (a process combined with the re-oxidation of Fe2+ to Fe3+ mediated by
ceruloplasmin). Senescent erythrocytes are engulfed by reticuloendothelial macrophages. Iron is
released from heme by heme oxygenase (HO1) and it can be either stored in ferritin or exported
back to the circulation, depending on systemic iron requirements. Iron export from macrophages
via FPN is also coupled to the activity of ceruloplasmin. Hepcidin produced by hepatocytes has the
ability to decrease cellular iron export by binding to FPN and inducing its endocytosis and degradation.
The expression of hepcidin is controlled by several factors including body iron stores and inflammation.
Pharmaceuticals 2019, 12, 5 3 of 28
The lung is the major organ for gas exchange and like all other organs it is exposed to
circulating iron. Additionally, lung cells are directly exposed to exogenous iron sources via inhalation
(e.g., cigarette smoke). A disruption of iron homeostasis in the lung is frequently associated with
respiratory diseases, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress
syndrome, and cystic fibrosis [9–11]. This review focuses on the regulation of pulmonary iron levels
and its functional importance as well as potential intrinsic and extrinsic factors modulating lung
iron homeostasis. We will further address the impact of iron in the pathogenesis of human lung
diseases as well as other diseases with a pathological lung phenotype associated with alterations in
iron metabolism.
2. Lung Iron Homeostasis
2.1. Balancing Lung Iron Homeostasis
Lungs are composed of numerous cell types that work together to ensure efficient gas exchange
between the atmosphere and the bloodstream. As every other cell, lung cells must acquire enough
iron to sustain metabolic demand, thus ensuring their survival and lung function. At the same time,
lung cells must prevent iron overload, oxidative stress, and resulting injury, which would ultimately
impair lung function. The risk of oxidative stress in the lung is increased due to the exposure to
physiologically high oxygen levels in the atmosphere. Lung cells are not only exposed to circulating
iron but also to iron present in inhaled particles, such as mineral aerosols generated by wind erosion
of soils or iron-rich air pollution particles [12,13]. In response to these challenges, the lung maintains
protective mechanisms to avoid oxidative damage. The epithelial surface of the respiratory tract is
covered by a thin layer of fluid containing high levels of antioxidant molecules, such as ascorbic
acid, reduced glutathione, and mucin [14]. Furthermore, human airway secretions contain transferrin
and lactoferrin, and glycoproteins are able to bind iron and maintain a chemically inert form [15,16].
Iron bound to transferrin or lactoferrin can be taken up by epithelial cells through their receptors,
namely transferrin receptor 1 (TfR1) and lactoferrin receptor (LfR), respectively, to be stored safely
bound to ferritin (Figure 2), a multimeric iron storage protein consisting of 24 subunits of heavy and
light chains capable of accommodating up to 4000 iron atoms [17–19]. Excess of pulmonary iron
caused by endogenous or exogenous factors can override these protective mechanisms and cause
pulmonary oxidative stress. Experimentally, this was tested by intravenously injecting iron-containing
compounds (e.g., iron dextran and ferric carboxymaltose) in rats that subsequently showed high levels
of pulmonary oxidative stress, indicated by increased levels of nitrotyrosine and protein carbonyl
modifications [20]. Likewise, pulmonary administration of Fe2O3 nanoparticles via inhalation also
generates ROS in the rat lung [21].
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take up the iron required for their metabolic needs from the lung vasculature via TfR1. Additionally,
airway epithelial cells also take up iron from the airway space via TfR1, LFR, DMT1 (associated
with the reduction of Fe3+ to Fe2+ by DCYTB), and possibly via ZIP14 or ZIP8. These cells store
iron intracellularly bound to ferritin or export it via FPN expressed at their apical surface. Alveolar
macrophages may take up free iron as well as iron bound to proteins from the alveolar space via
DMT1, TFR1 or lactoferrin receptor (LFR). They might further take up inhaled iron-rich particles
via phagocytosis. Alveolar macrophages are believed to be crucial in the maintenance of lung iron
homeostasis by st ring high amount of iron intracellularly bo nd to ferritin. It is still not clear if
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2.2. Pulmonary Iron Modulation is a Potent Intrinsic Defense Strategy Against Respiratory Pathogens
Respiration not only provides oxygen to support life but also exposes the respiratory system
to external pathogens. Iron homeostasis and immune responses are tightly connected, likely
reflecting the essential role of iron in the survival, proliferation, and virulence of most pathogens [22].
A central ost defense strategy is to limit iron availability f r extr cellular path gens by intracellular
s ques r tion [23]. Inflammatory cytokines (e.g., IL6) i uce th expressi n of the iro -regulated
hormone hepcidin that degrades the iron exporter FPN located in m crophages and duodenal
enterocytes, thereby reducing iron export to the circulation [24]. Additionally, transcription of FPN in
macrophages is reduced via the TLR4- or TLR2/TLR6-signalling pathways, further contributing to
inflammation-associated hypoferremia [25–27]. Indeed, failure to decrease systemic iron levels upon
infection strongly increases the susceptibility of hepcidin knock-out (KO) mice to some pathogens,
such as Vibrio vulnificus or Klebsiella pneumonia [28]. In line with this observation, individuals with
iron overload disorders, such as hereditary hemochromatosis, display a higher susceptibility to various
infectious diseases [29,30]. Moreover, supplementation of iron and folic acid in preschool children
increased the incidence of malaria and other infectious diseases in Pemba (Tanzania), an area with
high infectious bur ens [31].
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As iron plays a critical role in the development of infectious diseases, the maintenance of
low iron levels in the lung is crucial not only to prevent oxidative stress but also to sustain the
pulmonary defense against inhaled pathogens. A positive correlation between sputum iron content
and P. aeruginosa levels in clinically stable cystic fibrosis patients supports this idea [10]. Iron is
a strong regulator of P. aeruginosa survival and behavior, as 6% of its transcribed genes respond
to iron [32]. The success of this Gram-negative bacterium in colonizing the airways is in part
due to its ability to form biofilms. Interestingly, several studies showed that iron is necessary for
P. aeruginosa biofilm formation and application of iron chelators impairs this process by sequestering
free iron [33,34]. Based on these findings, pulmonary administration of high-affinity iron chelators
via inhalation might emerge as a possible therapeutic approach to fight P. aeruginosa lung infections
in cystic fibrosis patients [32,34]. Consistently, the incidence of respiratory infections in children
with mild-to-moderate iron-deficiency was substantially lower compared to iron-depleted children in
Kilimanjaro (Tanzania) [35]. Finally, an association between increased dietary iron intake and increased
odds of developing active pulmonary tuberculosis was observed in individuals from Zimbabwe [36].
Patients who underwent lung transplantation showed increased pulmonary iron levels in the
allografts after transplantation that possibly contributed to the risk of oxidative stress and lung
injury [37,38]. In addition, high iron levels in a tracheal allograft mouse model increased the risk for
A. fumigatus invasion, a well-known pathogen causing common respiratory infectious disease in lung
transplant recipients [39].
During evolution, microorganisms developed high-affinity iron uptake systems, such as
siderophores, to acquire iron from the host [22]. The host fights back by increasing the expression of
lipocalin-2, a protein mainly produced by neutrophils that binds to the siderophore enterobactin and
prevents its uptake by the pathogen [22]. During infection, lipocalin-2 is not only secreted by recruited
neutrophils but also from lung epithelial cells [40]. The importance of lipocalin-2 in sequestering iron
in the lung is highlighted by the observation that pneumonia caused by intratracheal instillation of
E. coli is aggravated in lipocalin-2 knock-out mice [40]. Furthermore, lipocalin-2 binding is specific and
does not prevent iron uptake and consequent colonization by bacteria that produce modified forms of
enterobactin or other types of siderophores [41].
2.3. Molecular Regulation of Lung Iron Homeostasis
Iron uptake, utilization, storage, and export must be coordinated to maintain cellular iron
homeostasis in every organ. The iron-responsive element (IRE)/iron-regulatory protein (IRP) system
plays a central role in this process by controlling the expression of iron-related proteins in response to
intracellular iron levels (Figure 3) [42,43]. Iron regulatory protein 1 and 2 (IRP1 and IRP2) interact with
conserved hairpin structures named iron-responsive elements (IREs) present in the 5’ or 3’ untranslated
regions (UTRs) of mRNAs of iron-regulated genes (Figure 3). In iron-deficient cells, IRPs bind to the
IRE in the 5’ UTR of ferritin light chain (FtL), ferritin heavy chain (FtH), FPN, and the transcription
factor HIF-2α (see below) mRNAs, inhibiting their translation [44–48]. Additionally, IRPs bind to
IREs located in the 3’ UTR of TfR1 or Dmt1 (see below) mRNAs, blocking their degradation [49–51].
Subsequently, in conditions of cellular iron deficiency, iron uptake increases while iron storage and
export decrease, resulting in higher intracellular iron availability. On the other hand, in iron-loaded
cells, IRPs cannot bind to IREs. IRP1 is converted from its RNA-binding form to a cytoplasmatic
aconitase containing a 4Fe–4S cluster and IRP2 is targeted for proteasomal degradation [52–54]. As a
result, iron storage and export are increased and iron uptake decreased.
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Figure 3. Cellular iron homeostasis: iron responsive element (IRE)/ iron regulatory protein (IRP)
system. IRP1 and IRP2 bind to IREs present in either the 5’ untranslated regions (UTR) or 3’ UTR of
mRNAs and regulate their translation and stability, respectively. In iron-depleted cells, IRPs bind to
an IRE localized in the 5’ UTR of mRNAs to repress translation, while IRP binding to IREs in the 3’
UTR stabilizes mRNAs. In iron-replete cells, IRP1 switches from its IRE-binding form to a Fe-S cluster
containing aconitase and IRP2 is degraded. The lack of IRP binding to IREs allows for the translation
of mRNAs containing an IRE in the 5’ UTR and degradation of mRNAs containing IREs in the 3’ UTR.
This mechanism counterbalances both cellular iron deficiency and iron overload. (Fpn—ferroportin;
FtL—ferritin light chain; FtH—ferritin heavy chain; HIF-2α—hypoxia-inducible factor-2α).
2.3.1. Control of Pulmonary Iron Uptake
Similar to most cells, lung cells express TfR1 and likely acquire transferrin-bound iron from
pulmonary vessels (Figure 2). Increased pulmonary iron levels in mouse models of iron overload are
associated with decreased pulmonary TfR1 mRNA levels, suggesting that the IRE/IRP regulatory
system controls the expression of iron-related genes in the lung [55,56]. In healthy humans,
approximately 30% of plasma transferrin is saturated with iron. In conditions of systemic iron
overload, which cause transferrin saturation to rise above 60%, non-transferrin-bound iron (NTBI)
accumulates. Exposure to high levels of systemic iron causes accumulation in different pulmonary cell
types, such as alveolar macrophages, epithelial cells, and vascular smooth muscle cells [55,56]. So far,
the exact iron uptake mechanisms are not understood. The lung expresses the NTBI importers DMT1,
ZIP14, and ZIP8, that may further contribute to the iron loading under high systemic and/or local
iron levels.
The divalent metal transporter 1 (DMT1) is localized at the brush-border membrane of duodenal
enterocytes and was first discovered due to its crucial role in dietary iron absorption (Figure 1) [57].
Dietary inorganic ferric iron (Fe3+) needs to be reduced to ferrous iron (Fe2+) by the ferrireductase
duodenal cytochrome B (DCYTB) before being transported from the duodenal lumen into the cytosol
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of enterocytes via DMT1 [58]. Airway epithelial cells express both DMT1 and DCYTB, and therefore
are likely able to take up NTBI from the airway space (Figure 2) [59,60]. How lung DMT1 expression
is regulated in response to pulmonary iron levels is unclear. Different Dmt1 mRNA isoforms are
expressed in the lung, including one isoform harboring an IRE in the 3’UTR and another isoform
lacking the IRE [61,62]. Increased iron levels inactivate the IRE/IRP system and cause a decrease
in the mRNA levels of the IRE-containing DMT1 isoform (Figure 3). Consistently, lower mRNA
levels of this isoform are observed in the iron-loaded lung of a murine mouse model of hereditary
hemochromatosis type 4 [56]. In addition, lower pulmonary DMT1 mRNA and protein levels were
also reported in the iron-loaded lung of hepcidin deficient mice [55]. By contrast, DMT1 protein
levels remain unchanged upon lung iron loading via intraperitoneal injection of iron-saccharate [63].
Moreover, another group observed an increase in the non-IRE DMT1 isoform in the rat lung, following
instillation with ferric ammonium citrate, without differences in the levels of the IRE-containing DMT1
isoform [64]. Future studies are required to further dissect the molecular mechanisms regulating Dmt1
expression in the lung.
NTBI can also be taken up by cells via ZRT/IRT-like protein (ZIP) 14. Genetic inactivation revealed
that ZIP14 is a key player for NTBI uptake by hepatocytes under iron overload conditions [65]. Besides
hepatocytes, ZIP14 is expressed by cells in other tissues such as the pancreas and the heart [65,66].
In addition, ZIP14 is detected in airway epithelial cells, and protein levels were shown to increase in
the iron loaded murine lung [63]. In 2012, another ZIP protein able to transport iron, named ZIP8, was
reported. It is abundantly expressed in the human lung [66]. A disruption in both alleles of the mouse
ZIP8 gene causes lethality between the gestational day 18.5 and 48 hours postnatal [67]. Interestingly,
the newborns present with anemia and reduced iron levels in some tissues, including the lung [67].
Finally, in conditions of intravascular hemolysis, lung cells can also be exposed to hemoglobin
and heme-iron circulating in the bloodstream. When released from RBCs, hemoglobin forms a complex
with the glycoprotein haptoglobin in the plasma, which is mainly taken up by reticuloendothelial
macrophages; heme released from hemoglobin in the blood forms a complex with the glycoprotein
hemopexin and is taken up by liver parenchymal cells [68]. In vivo studies have shown that the uptake
of hemoglobin-haptoglobin and heme-hemopexin complexes by the lung is relatively low [69–72].
Nevertheless, alveolar macrophages express the haptoglobin receptor CD163 and the hemopexin
receptor CD91, and therefore are likely able to take up these complexes [73,74]. Alveolar macrophages
exposed to heme upregulate the expression of HO-1 that is responsible for heme degradation and
protection against the toxic effects of this prosthetic group [75,76].
2.3.2. Iron Storage in the Lung
Lung cells store iron intracellularly bound to ferritin, keeping it in a non-toxic ferric form and thus
preventing oxidative damage. Consistent with the role of the IRE/IRP system in controlling ferritin
expression, pulmonary ferritin levels increase upon lung iron loading in murine mouse models [55,56].
Higher levels of ferritin were also detected in the bronchoalveolar lavage fluid of individuals instilled
with iron-containing particles [77]. When needed, iron stored in ferritin can be made available to the
cell. In conditions of low levels of intracellular iron, NCOA4 (Nuclear Receptor Coactivator 4) targets
the ferritin complex to degradation in autolysosomes and iron is released into the cytoplasm [78,79].
Genetic inactivation of NCOA4 impairs iron mobilization from stores in several tissues such as the
liver and the spleen [80]. Future studies must address the possible role of NCOA4 in the mobilization
of ferritin-stored iron in lung cells.
2.3.3. Iron Export from the Lung
The only known iron exporter FPN is expressed in the lung, too, albeit at a much lower level
compared to the spleen, the key iron recycling site [55]. Using an in vitro model, it was shown that
polarized airway epithelial cells export iron through their apical surface [81]. FPN expression at this
site was confirmed using immunohistochemical analysis [55,81]. Additionally, several studies reported
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an association between increased pulmonary iron content and higher protein levels of FPN in this
organ [63,82]. Increased levels of FPN are likely a consequence of the inactivation of the IRE/IRP
system and an increase at the transcriptional level. Iron export via FPN is combined with iron oxidation
from Fe2+ to Fe3+, mediated by ceruloplasmin (or hephaestin in the basal membrane of duodenal
enterocytes) (Figure 1) [83,84]. Interestingly, ceruloplasmin was detected in human bronchial lavage
fluid, suggesting that it might be involved in FPN-mediated iron export in the lung [15]. Note that
the pH of lung fluids (e.g., the alveolar lining fluid) may affect the complex process of spontaneous
oxidation of ferrous to ferric iron following a sigmoid shaped oxidation rate in relation to pH [85].
Therefore, changes in pH may alter the iron redox-states within the alveolar lining fluid, that in turn
would affect trans-epithelial iron uptake and intracellular iron availability.
2.3.4. Pulmonary Hepcidin Expression
Hepcidin is mainly produced and secreted by hepatocytes to control systemic iron levels [1].
Of note, low levels of hepcidin are also detected in other tissues, such as the heart, kidney, and
lung [55,86–88]. Hepatocyte-specific hepcidin knock-out mice recapitulate the hemochromatosis
phenotype observed in constitutive hepcidin deficient mice, indicating that extra-hepatic hepcidin
is not enough to maintain systemic iron homeostasis [89]. However, recent studies proposed the
existence of cell-type specific regulatory circuitries in some tissues. For example, through the analysis
of mice with cardiomyocyte-specific deletion of hepcidin, a cell-autonomous role for cardiac hepcidin
in maintaining cardiac iron homeostasis was identified [86]. It is still not clear whether there is a local
role of hepcidin in the lung. Some reported that the induction of pulmonary hepcidin expression
by bacterial lipopolysaccharide (LPS) instillation does not affect FPN protein levels in the lung [55].
Consistently, others showed that an increase in hepcidin expression in human bronchial epithelial
cells in vitro does not cause a decrease in FPN protein levels [90]. By contrast, an increase in lung FPN
protein levels was observed upon knocking down hepcidin in airway epithelial cells in a mouse model
of sepsis-induced acute lung injury [91]. Overall, future studies are necessary to fully understand the
potential role of lung hepcidin in pulmonary iron homeostasis.
2.3.5. Alveolar Macrophages
Alveolar macrophages frequently accumulate iron in lung diseases and conditions of iron
overload [11,55,56,63]. While splenic and liver macrophages are essential to recycle iron from aged
RBCs, the location of alveolar macrophages in the alveolar space suggests that at least in healthy
conditions these cells do not contribute to hemoglobin-derived iron recycling. Instead, alveolar
macrophages are expected to have a protective role by scavenging the excess of iron in the lung
(derived from inhaled iron particles or from plasma iron) thereby limiting its availability to induce
oxidative damage [92]. The expression of TfR, LfR, and DMT1 was reported in alveolar macrophages,
indicating that these cells might be able to take up iron-bound to proteins as well as ‘free’ iron from
the alveolar space, storing it intracellularly in ferritin (Figure 2) [55,93–95]. However, it is still not
known which iron-uptake mechanism is predominant under physiological conditions. It is further
possible that alveolar macrophages take up iron-rich particles from the alveolar space via phagocytosis.
Whether these macrophages express FPN under normal iron conditions is unclear. In earlier work,
we did not detect FPN in alveolar macrophages isolated from the bronchoalveolar lavage of wild-type
mice by immunocytochemical analysis [56]. Similarly, others reported very low protein levels of
FPN in these cells by western blot analysis [55]. In contrast, another group detected FPN at the cell
membrane of freshly isolated alveolar macrophages, that was significantly reduced in the presence of
hepcidin [93]. Consistent in most studies is the observation that higher levels of FPN were detected
in alveolar macrophages in murine and rat models under iron loading conditions [55,56,82]. Finally,
alveolar macrophages express hepcidin, which increases upon an inflammatory stimulus, but not upon
iron loading [55,93].
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2.4. Modulating Factors of Lung Iron Homeostasis
Pulmonary iron levels depend on plasma iron availability. Consequently, alterations in systemic
iron levels have an impact on lung iron content. Mice injected intraperitoneally with iron-saccharate
or rats maintained on a high iron diet increased lung iron levels compared to control animals [63,96].
Similarly, mice with genetic iron overload due to either hepcidin deficiency or a mutation in FPN
that confers resistance to hepcidin binding show pulmonary iron accumulation [55,56]. Interestingly,
high lung iron content was also observed in liver-specific hepcidin deficient mice [55]. This finding
strengthens the hypothesis that lung iron loading occurs as a consequence of increased plasma iron
levels and not due to the absence of a functional hepcidin/ferroportin system in the lung. By contrast,
an increase in lung iron content was not observed in HFE deficient mice with a less severe form of
hemochromatosis [87]. Note that HFE is a positive regulator of hepcidin and in its absence hepcidin
expression is attenuated [97].
Patients with thalassemia major are hallmarked with ineffective erythropoiesis and therefore
require frequent blood transfusions to ensure an adequate oxygen supply to the body [98]. Red blood
cells contain high amounts of iron (1 mg of iron per milliliter of erythrocytes [6]). As a consequence of
multiple transfusions and due to the absence of a regulated way to excrete iron, these patients develop
massive systemic iron overload [99]. Iron accumulation was detected in alveolar macrophages from
these patients further supporting the hypothesis that increased systemic iron levels elevates pulmonary
iron content [100,101].
On the other end of the spectrum, iron deficiency does not seem to alter pulmonary iron levels.
Iron deficiency induced by repeated bleeding of mice or a low iron diet (20–25 ppm Fe versus
control diet with 200 ppm Fe) in rats caused decreased iron content in liver and spleen but not
in the lung [63,102]. Contrasting these studies, rats fed for three weeks on an iron-deficient diet
(5,9 ppm Fe) showed a reduction in lung iron levels compared with control animals fed on a diet
containing 128 ppm Fe [103]. Differences may reflect the degree of systemic iron deficiency achieved
in different studies, whereby the lung iron content may only be altered under conditions of severe iron
deficiency. It would be of interest to analyze pulmonary iron levels in mice with genetic iron deficiency,
such as Tmprss6 knock-out mice, an animal model with severely impaired iron uptake due to elevated
hepcidin levels [104]. Note that TMPRSS6 is a well-known negative regulator of hepcidin [105].
Approximately 60 to 70% of the body’s iron is localized in RBCs. The lung vasculature accommodates
the entire cardiac output, allowing almost all RBCs to pass through the alveolar capillaries in order
to be loaded with oxygen. Conditions that affect alveolar capillary integrity/permeability (e.g.,
Goodpasture’s disease) [106] can lead to hemorrhage into the alveolar space. These patients show
alterations in lung iron homeostasis with increased iron levels in alveolar macrophages, likely
resulting from hemoglobin-derived iron from phagocytosed RBCs [107]. Such cases are examples of
disorders that modulate lung iron homeostasis but are not a direct consequence of alterations in iron
regulatory mechanisms.
3. Environmental Factors that Impact Lung Iron Homeostasis
Environmental factors also affect systemic and lung iron homeostasis. For example, global air
pollution and exposure to cigarette smoke are well known to alter pulmonary iron homeostasis.
Another potent environmental factor is the exposure to high altitude, which is further exaggerated
when combined with physical activity, e.g., during mountaineering at high altitude or altitude training.
Pollutants from soil and drinking water (e.g., heavy metals) can significantly disrupt iron homeostasis
as well. Finally, thermal stress induced by extremely warm or cold environmental conditions may also
affect iron metabolism but are not within the scope of the present review.
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3.1. The Impact of Air Pollution and Cigarette Smoke on Iron Homeostasis
According to a recently released WHO news report [108], it is estimated that 9 out of 10 people
worldwide breathe polluted air, resulting in 7 million additional deaths each year. Fine particles from
polluted air penetrate the airways and subsequently reach the cardiopulmonary system causing a
variety of diseases such as stroke, heart disease, COPD, lung cancer, and pneumonia [108]. These
airborne fine particles, including iron-containing and iron-binding particles, accumulate in the lower
respiratory tract, e.g., within the bronchial epithelium. Several groups reported that instillation
of iron-containing particles in mice and rats induces increased cellular oxidative stress and lung
inflammation [21,109].
Apart from air pollution, cigarette smoke also causes fine (iron) particle exposure of the airways
and modulates lung iron homeostasis [110]. The cigarette smoke-induced lung injury was shown
to be particle related and is clinically associated with a loss of lung function, increased bronchial
hyper-responsiveness, and a pathological lung tissue transformation (e.g., emphysema, fibrosis) [111].
The tracheal lavage from rats exposed to cigarette smoke contained higher levels of iron, transferrin
and ferritin. Consistently, the lung non-heme iron content was increased. By contrast, serum iron
and transferrin concentrations were reduced in these exposed rats. Additionally, serum ferritin and
liver non-heme iron concentrations were increased, indicating a combined disturbance of lung and
systemic iron homeostasis [110]. A similar expression pattern in the bronchial lavage of smokers with
or without COPD was confirmed by the same authors.
Overall, the majority of cigarette smoke induced lung diseases are of inflammatory nature and
strongly depend on activated immune-modulatory signaling pathways [112]. It was suggested that
particle-induced ROS-driven mitochondrial dysfunction could have a key role in the pathophysiology
of air pollution/cigarette smoke related lung diseases [113]. Although the underlying molecular
mechanisms of how environmental fine particle exposure affects pulmonary cellular iron homeostasis
are not fully understood, there is a fundamental link to the most globally frequent and deadliest
respiratory diseases such as pneumonia, COPD, and lung cancer.
3.2. Does Environmental Pollution Alter Iron Homeostasis?
The environmental iron content depends on the soil iron content in given geographical regions
and often influences iron levels in the drinking water. For example, the Tibetan Plateau contains a
higher percentage of soil iron in comparison to the Chinese region [114]. As Tibetans often live from
farming and mining, this living habit suggests a higher exogenous exposure to iron. Unfortunately,
reports are not available as to whether this affects iron homeostasis and health in Tibetans. On the
other hand, it is well-known that other environmental pollutants derived from soil and drinking
water, such as persistent organic pollutants, heavy metals, and pesticides, significantly affect body iron
homeostasis with toxic effects on organic functions [115]. Finally, the habit of open-fire cooking has
to be considered as a source of iron pollution, too. As systemic iron availability directly affects lung
iron availability these environmental factors may also impact on lung function and health in exposed
individuals. Future research is needed to prove this assumption.
3.3. High-Altitude Exposure and Physical Exercise
More than 140 million people permanently live at altitudes of 2500 m above sea level and millions
of other people travel to high altitude every year [116]. Adequate iron homeostasis is essential
for oxygen uptake, transport, and delivery in the body, ultimately allowing aerobic metabolism.
Therefore, it is not surprising that iron metabolism and aerobic metabolism are strongly linked to
each other. Humans can, at least to a certain extent, adapt to high altitude and subsequently also to
reduced atmospheric oxygen partial pressure levels, as exemplified by the highest permanent human
settlements at altitudes of 5500 m above sea level at the Qinghai-Tibetan plateau in Asia [117]. On the
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other hand, exposure to high altitude can also lead to pathological maladaptations, which result in the
well-known acute and chronic forms of high-altitude-related diseases [118].
At the systemic level, the mechanisms by which the human body can adapt to high altitude by
altering iron acquisition have been recently discussed. This involves key organs of iron homeostasis
such as the liver, the bone marrow, and the small intestine (duodenum), as well as signaling molecules
such as erythropoietin, hepcidin, and erythroferrone that interact to control plasma iron levels [119].
Briefly, the recently discovered erythroid regulator erythroferrone (ERFE) [120] is released mainly from
erythropoietin (Epo)-stimulated erythroblasts to suppress hepcidin production in hepatocytes resulting
in increased iron absorption in the duodenum and iron export from reticuloendothelial macrophages.
This elevates systemic iron availability required for RBC synthesis [121]. Higher levels of circulating
RBCs improve tissue oxygenation by increasing blood oxygen transport capacity to compensate for
the reduced alveolar oxygen diffusion at high altitude.
Oxygen demand increases upon physical exercise at high altitude. As a consequence, the iron
turnover increases by a combination of an elevated iron demand due to exercise induced enlargement
of red blood cell volume and an enhanced iron loss due to exercise induced sweating, hemolysis,
hematuria, gastrointestinal bleeding, and, as recently reported, a modification of hepcidin levels [122].
Furthermore, iron deficiency is quite common in athletes, especially in females, and significantly
compromises exercise performance [123], especially when performing at high altitude [124]. A very
recent in vitro study found that iron chelator deferoxamine (DFO)-induced intracellular iron deficiency
reversibly compromises contractility and relaxation of human cardiomyocytes by a significant
impairment of mitochondrial respiration [125]. This indicates a direct impact of iron deficiency
on cardiac function.
At the pulmonary level, convincing evidence exists for a crucial role of iron homeostasis in the
maintenance of physiological lung function as well. This becomes particularly evident under stress
conditions, such as high-altitude exposure. Here, the functional units of the cardiopulmonary system,
namely the airways, the pulmonary vasculature, the respiratory control, the respiratory muscles, and
the heart must interact in a precise and integrative manner. Balanced iron availability is important
for every single functional compartment of the cardiopulmonary system to successfully adapt to
high altitude.
Apart from the previously mentioned impact of cellular iron scavenging on human cardiac muscle
cell function, other experimental studies showed that the chronic application of the iron chelator
ciclopirox olamine (CPX) negatively affected the acute hypoxic ventilatory response of rats [126,127].
This response is crucial for high altitude adaption and is primarily mediated by the carotid bodies, the
main arterial oxygen-sensing organs [128]. Of note, structural changes and altered HIF-1α expression
(see below) were found in the tissue of harvested carotid bodies of CPX-treated rats [129,130].
The airways and the pulmonary vasculature must also respond in an orchestrated manner to
optimize oxygen transfer and gas exchange within the lungs at high altitude and the functional
quality of this process is reflected by an improved ventilation/perfusion (V/Q) balance [131].
Physiological studies clearly demonstrated the importance of iron balance for the hypoxic pulmonary
vasoconstriction (HPV), also known as the Euler-Liljestrand reflex, and generally for the response of
the pulmonary vasculature to acute and sustained hypoxia [132]. By infusing iron or the iron chelator
DFO in healthy adults, the authors showed that iron infusion can abolish the HPV sensitization after
re-exposure to hypoxia. In contrast, DFO application increased the effect. An exaggerated HPV is
associated with high altitude-related diseases (see disease section). Notably, the ventilatory response of
the study subjects to acute hypoxia was also affected by the different treatment interventions [132,133].
Finally, the Tibetan highlanders living on the Tibetan plateau represent the most successful
human example of high-altitude adaption, having a unique setting of a potentially replenished iron
status [134], an increased pulmonary capacity, and a blunted hypoxic ventilatory response [135],
a naturally-selected and genetically-based hypo-responsive HIF-signaling system [136], and a superior
physical capacity at high altitude, which led to their nomination as ‘King of the mountains’ [137].
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4. The Role of Heterodimeric Hypoxia-Inducible Factors 1 and 2 (HIF-1 and HIF-2) in the Lung
During mammalian lung development, a close interaction between airway epithelium and
vascular endothelium occurs, which is driven by hypoxic stimuli. The HIF-VEGF-axis is essential
for this process. HIF-1 and HIF-2 are heterodimeric transcriptional key regulators of epithelial,
mesenchymal, and vascular lung morphogenesis, which are composed of an oxygen-regulated
α-subunit and a constitutively expressed β-subunit, the latter also named ARNT. HIF-1α expression is
known to dominate early lung development, while HIF-2α up-regulation starts at the saccular stage.
Although global deficiency of HIF-1α results in lethality at embryonic day 11 (E11) in mice, the deletion
of HIF-2α causes defective lung development, decreased surfactant production, postnatal respiratory
distress, and neonatal lethality [138,139].
Several recent reviews have discussed the cellular interference between iron- and oxygen-sensing
within the lungs [133,135,140–142]. Mammalian cells seem to have multiple molecular structures for
sensing intracellular iron and oxygen levels of which some also act as metabolic sensors, while the
mitochondrion seems to be the central sensing organelle. The process of intracellular oxygen sensing
and signaling has been described in great detail recently [143–145] and thus these mechanisms will not
be repeated here.
Although the prolyl-hydroxylase domain (PHD)-HIF-oxygen-sensing cascade and the
IRP-IRE-signaling machinery are ubiquitously expressed within mammalian organs including the
lungs [146,147], the cellular interferences between the two pathways as shown in other organs
(e.g., liver and kidneys) have not yet been translated to the lungs. However, the responses of the
cardiopulmonary system to alterations of iron- and oxygen availability as reported previously, strongly
suggest their presence also within the lungs.
First of all, ferrous iron (Fe2+) is a critical co-factor apart from the presence of oxygen, ascorbate,
and 2-oxoglutarate (2-OGH) for the function of PHDs (PHD1-3), which act as intracellular oxygen
sensors that require iron to regulate HIF-degradation [143]. The PHD2-HIF2-signaling pathway
is believed to play an important role in the hypoxic response of the lungs [146] and is affected
by alterations in iron availability. In low oxygen conditions, IRP1 activity is reversible reduced
while IRP2 activity is increased, which suggests a different role of the two iron regulatory proteins
(IRPs) in this context [140]. It was shown that during hypoxic exposure HIF-1α can interact with
the hypoxia response elements (HREs) of the IRP1 5’-regulatory region and down-regulate IRP1
expression (HIF-1α-IRP1-axis) [148]. The increase in the levels of IRP2 upon hypoxic exposure is
caused by inhibition of its degradation mediated by the iron- and oxygen-dependent F-box and
Leucine Rich Repeat Protein 5 (FBXL5) [43,149]. As mentioned earlier, HIF-2α mRNA has an IRE in
its 5’ UTR, allowing the translational regulation of HIF-2α via IRPs, dependent on intracellular iron
availability [48]. The HIF-2α-IRE primarily interacts with IRP1 [150]. The IRP1-HIF-2α-signaling axis
is proposed to be one of the most important links between intracellular iron homeostasis and oxygen
sensing [151].
We and others [147] speculate that this mechanism also occurs in the lungs and is potentially
involved in the response of the pulmonary vasculature and the airways to acute and sustained
hypoxia. Early on, it was shown that the exposure of cells to the iron chelator DFO induces HIF-1α
expression [152], suggesting that intracellular iron deficiency has an hypoxia-mimicking effect. It is
now well-known that several HIF target genes are involved in the regulation of iron homeostasis.
For example, HIFs activate the transcription of genes encoding for TfR1, DMT1, heme oxygenase 1
(HO-1), FPN, and ceruloplasmin [144]. Additionally, during hypoxia, HIF-1α induces the microRNA
miR-210, which represses the iron sulfur cluster units 1 and 2 (ISCU1/2), proteins that facilitate the
assembly of Fe-S clusters [153,154]. Thus, the miR-210-ISCU1/2-Fe-S cluster axis is proposed to be
another important interference pathway between intracellular iron homeostasis and oxygen sensing
within the lungs.
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5. Linking Lung-Related Diseases to Disrupted Lung Iron Homeostasis
A growing number of acute and chronic lung diseases as well as other diseases with a pathological
manifestation within the lung are associated with disrupted lung iron homeostasis, leading to either
iron deficiency or iron overload (summarized in Table 1). These diseases were also reviewed by other
research groups, albeit with a different primary focus [19,133,135,155–157]. Generally, the lungs are
not considered as a primary iron regulating/storing organ, especially in contrast to the liver, the
skeletal muscles, the duodenum, the reticuloendothelial system, and the bone marrow including the
RBC pool [2]. However, the regulation of iron homeostasis within the mammalian lungs is tightly
controlled (iron content range: 0.4-0.9 mg/g lung tissue according to [155]) in order to maintain proper
lung function and also to adapt to changes in iron needs upon changing body conditions, e.g., during
exposure to environmental stress as experienced at high altitude. Thus, the iron balance within the
lungs is crucial for health and disease. Below we mention selected lung and lung-related diseases
in which a link to disturbed iron homeostasis was established. It is beyond the scope of the current
review to mention all pulmonary diseases in which iron eventually plays a role.







Asthma Obstructive ↔ to ↓ ↓ [156,158,159]
ARDS Shunt, V/Q mismatch ↔ ↑ [9,19,156,157,160]
CF Obstructive ↔ to ↓ ↑ [19,156,161,162]
CMS V/Q mismatch ↔ to ↓ 1 ↓ 1 [133,135,163,164]
COPD Obstructive ↔ to ↓ ↑ [155–157,165,166]
HAPE Diffusion Limitation ↔ to ↓ ↓ [167,168]
IPF Restrictive ↔ ↑ [156,169,170]
Lung CA N.A. ↔ to ↓ ↑ [156,157,171–176]
PAP Shunt ↔ ↑ [19,156,177,178]
PH V/Q mismatch ↔ to ↓ ↓ [133,135,179–185]
TM Restrictive ↔ to ↑ 1 ↑ 1 [98,100,186–189]
ARDS: Acute respiratory distress syndrome; CF: Cystic fibrosis; CMS: Chronic mountain sickness; COPD: Chronic
obstructive pulmonary disease; HAPE: High-altitude pulmonary edema; IPF: Idiopathic pulmonary fibrosis; Lung
CA: Lung cancer; PAP: Pulmonary alveolar proteinosis; PH: Pulmonary hypertension; TM: Thalassemia Major;
V/Q mismatch: Ventilation/Perfusion mismatch; N.A.: Not applicable;↔ normal iron availability; ↓ reduced iron
availability; ↑ increased iron availability; 1 Treatment induced.
5.1. Acute High-Altitude Illnesses and High-Altitude Pulmonary Edema (HAPE)
The classical high-altitude illnesses are also comprised under the term ‘mountain sickness’. Acute
mountain sickness (AMS) is a common manifestation of high-altitude illness and related to a cerebral
intolerance to hypoxia. The same is the case in high-altitude cerebral edema (HACE), a severe and life
threating condition [167,190]. In the lungs, the development of high-altitude pulmonary edema (HAPE)
can occur in unacclimatized healthy individuals at high altitude (≥ 2500 m above sea level) within 1–5
days upon arrival [167,190,191]. The early clinical symptoms are excessive exertional dyspnea, mild
cough, chest tightness, and reduced exercise capacity, which can continue to worsen with dyspnea at
rest and cough as the edema progresses. In the advanced stage, it can lead to gurgling sounds in the
chest and pink frothy sputum. The chest radiograph shows a patchy to confluent edema distribution.
The bronchoalveolar lavage shows protein-rich exudate and mild alveolar hemorrhage. Although the
exact pathophysiology is not fully understood, it is widely accepted that HAPE is primarily induced
by hemodynamic changes within the pulmonary circuitry [167,190,191]. A recent field study reported
elevated serum hepcidin levels in HAPE patients exposed to high altitude in comparison to control
subjects, that was correlated with higher levels of IL6 [168]. Although no correlation between serum
iron levels and pulmonary arterial systolic pressure (PASP) was found in that study, the cellular iron
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availability within the lungs might have been altered in these HAPE patients, which is critical for
the hypoxic pulmonary vasoconstriction (HPV) response. Interestingly, the baseline PASP values
in the later HAPE patients were already significantly elevated when compared to healthy controls,
indicating a different pre-setting of the pulmonary vasculature tone. Of note, C-reactive protein (CRP)
levels were also significantly increased in HAPE patients at high altitude, which may have interfered
with serum ferritin levels but also other iron parameters and thus these values have to be interpreted
with caution [192]. Overall, an a priori iron status check before ascending to high altitude may help
mountaineers to optimize the acclimatization process leading to an increased exercise performance
and potentially prevent an iron depleted status with eventually negative health consequences at
high altitude.
5.2. Chronic Mountain Sickness (CMS)
CMS or Monge’s disease is a highly prevalent disease in high-altitude residents such as
the Andeans, with exception of Tibetans where CMS is very rarely seen [193]. The hallmark
characteristics of CMS are accentuated hypoxemia, excessive erythrocytosis (women: Hb ≥ 190
g/L, men: Hb ≥ 210 g/L), and pulmonary hypertension, which often results in right ventricular
enlargement and hypertrophy, and in the later disease stage, leads to chronic heart failure. Therapy
usually comprises of regular phlebotomy [163]. Iron deficiency itself, e.g., induced by the iron chelator
DFO, is associated with an elevated pulmonary vascular resistance (PVR), as observed during exposure
to hypoxia [194]. In this context, two randomized placebo-controlled trials were performed [164].
In the first trial, they showed that a single infusion of iron lead to 40% reduction of the pulmonary
hypertensive response in healthy sea-level residents after exposure to high altitude (4340 m above
sea level). In the second cross-over trial, they could show that repeated isovolemic venesection
(2 L of blood) was associated with a 25% increase in PASP in CMS patients. Although the subsequent
iron replacement did not acutely reverse the effect of iron deficiency on PASP in their setting, the
authors argued that the chosen time window might have been too short and further concluded that
careful adjustment of iron balance might be a promising strategy to ameliorate the severity in CMS.
In summary, it still needs to be proven by future clinical trials whether tight iron status monitoring
eventually in combination with therapeutic iron correction improves disease severity and quality of
life in CMS patients.
5.3. Pulmonary Hypertension (PH)
PH is a complex pathophysiological state characterized by a mean pulmonary artery pressure
above 25 mmHg at rest, assessed by catheterization of the right heart. PH is currently subdivided
into five different groups [195] and can lead to pulmonary vascular remodeling, right ventricular
hypertrophy, and right heart failure (for further detailed clinical information, see [179,196]). A central
role of an imbalance between iron homeostasis and oxygen sensing in the pathophysiology of PH
was recently discussed [180,181]. The authors proposed a model of combined inflammation driven
(via the IL-6-STAT3-hepcidin axis) iron deficiency and exaggerated activation of HIFs. In line with
this, it was shown that IRP1-/- mice develop polycythemia and PH via translational de-repression
of HIF-2α [182]. Moreover, the same authors also reported that the cultured pulmonary endothelial
cells of IRP1-/- mice showed elevated HIF-2α expression levels. Additionally, rats fed on an iron
deficient diet have higher levels of HIF-1α and HIF-2α in the lungs, which was associated with an
increased pulmonary artery pressure (PAP) and pulmonary vascular resistance [197]. In humans,
it was reported that iron deficiency is quite common in idiopathic PH patients [183]. Recent association
studies between iron deficiency and PH prevalence suggest that the PH-subtype and eventually also
ethnicity may play role in this context [198,199]. These studies together, with the previously reported
applied lab studies [132] and clinical trials in humans [164,200], clearly suggest a protective effect of
iron against PH and hypoxia-related diseases.
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On the contrary, strong positive iron shifts, e.g., in iron overload conditions seem to induce
opposite effects, potentially via increased oxidative stress [201]. Indeed, a very recent animal
study found that chronic iron overload of rats via daily iron-dextran injections (i.p.) for 28 days
induced vascular hyperreactivity and inward remodeling of pulmonary arteries, as well as heart
dysfunction [202]. Interestingly, it was recently found that miR-210 was up-regulated in several
PH animal models and that the inhibition of mir-210 significantly reduced pulmonary pressure
and vascular remodeling in a PH animal model [203], further suggesting a significant role of the
miR210-ISCU1/2-Fe-S cluster axis in the PH pathophysiology [184]. Although the lungs seem to have
a well-balanced ‘buffer capacity’ for iron, an excessive disruption of iron balance in either direction
has detrimental consequences on cardiopulmonary function. Overall, iron homeostasis and HIF
oxygen-sensing seem to be crucial in the pathology of PH. Accordingly, therapeutic modifications of
these interacting signaling pathways hold great promise for PH patients.
5.4. Chronic Obstructive Pulmonary Disease (COPD)
COPD is meanwhile the third leading cause of death worldwide, inducing a significant global
socioeconomic burden. Tobacco smoking is the most well-known risk factor for the development of
COPD and also for lung cancer. COPD is typically marked by chronic respiratory symptoms and airflow
limitations, which are caused by small airways disease and parenchymal destruction (emphysema).
The key symptoms of COPD are shortness of breath and dyspnea, as well as chronic cough and
sputum [165,204]. COPD pathophysiology is complex, however chronic systemic inflammation
potentially triggered by cigarette-induced ROS formation is suspected to be a central aspect of it [205].
Considering the main cause (cigarette smoke) and patho-mechanism (chronic inflammation), it is
highly suggestive that COPD is also linked to a disturbance of iron homeostasis. The special setting
in COPD of local iron containing and non-containing particle load of airways and potential systemic
iron deficiency would suggest a shift towards a mixed iron status. Importantly, cigarette smoke not
only contains a certain quantity of iron particles but also over 4000 chemicals of which 100 are known
carcinogens and 900 suspected carcinogens. A recent large cohort study found that in both smokers
and non-smokers, certain markers of iron homeostasis, such as serum ferritin concentration, serum
iron concentration, and transferrin saturation, were associated with critical parameters of lung function
(e.g., positive correlation for all three markers in both groups combined with forced vital capacity and
forced expiratory capacity) [206]. Another indicator for the presence of disrupted iron homeostasis
is the high prevalence of anemia and systemic iron deficiency in COPD patients. The prevalence of
anemia in two different cohorts of COPD patients ranged between 23% to 33% [207,208]. In another
COPD patient cohort, it was found that iron deficiency was associated with an increased frequency of
self-reported exacerbations and reduced exercise capacity [209].
It has been recently proposed that in patients with COPD, pro-inflammatory cytokines (e.g., IL-6)
trigger increased hepatic hepcidin expression and secretion [155]. This causes FPN degradation
and subsequently reduces cellular iron export into the blood stream, likely resulting in the systemic
iron deficiency and anemia observed in these patients. On the other hand, alveolar macrophages
from COPD patients were shown to accumulate iron and the percentage of iron-loaded macrophages
increased with disease severity [11]. Another team demonstrated that IRP2-/- mice were protected
from cigarette smoke-induced experimental COPD [166]. These authors also demonstrated that IRP2
increased mitochondrial iron content and concentrations of cytochrome c oxidase (COX), resulting in
impaired mitochondrial function and subsequently COPD in cigarette smoke-exposed mice. On the
contrary, mitochondrial iron chelator or a low-iron diet protected mice from cigarette-induced COPD.
Overall, regular monitoring of iron status and eventual therapeutic modulation of local and systemic
iron homeostasis may avoid the negative consequences of lung iron overload and systemic iron
deficiency in COPD patients.
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5.5. Asthma
Asthma and COPD belong to the subgroup of obstructive pulmonary diseases [158]. The potential
role of a disrupted iron homeostasis in asthma was reviewed in great detail recently [159]. Briefly,
the author reported profound evidence of disturbed iron homeostasis in asthma by systematically
evaluating the known demographic (e.g., ethnicity), physiologic (e.g., exercise), and pathologic
(e.g., infections) asthma determinants in the context of iron availability and concluded a setting of
absolute or functional iron deficiency in asthma, which may have therapeutic implications in the future.
5.6. Cystic Fibrosis (CF)
CF is a severe genetic pulmonary disorder triggered by impaired function of the anion transporter
CF transmembrane conductance regulator (CFTR) that results in increased secretion of abnormally
viscous mucus and at the clinical level, CF is characterized by chronic bacterial airway infection
(e.g., Pseudomonas aeruginosa), prominent neutrophilic inflammation, mucus accumulation within the
airways, and progressive bronchiectasis (formation of irreversible airway enlargements). The structural
changes within the lungs can be visible early using chest imaging. The host-defense defect in the
airways of CF patients plays a central role in the disease pathophysiology and leads to chronic
airway infections with inflammatory driven airway remodeling [161]. Evidence of disturbed iron
homeostasis in CF was found in experimental CF models and also in humans suffering from CF;
a setting of systemic iron deficiency and abnormal local iron sequestration within the airway cells
were reported [156]. Indeed, elevated iron levels were found in the bronchoalveolar lavage, sputum,
macrophages, and in explanted lung tissue from CF patients compared to healthy controls [162].
Furthermore, an increased expression of ferritin, DMT1, and FPN was found in the lung tissue of these
patients. Overall, the reported disruption of host iron homeostasis within the lungs of CF patients
might be a therapeutic target, especially to reduce chronic airway infections [210]. Alternatively,
a recent study showed that it is also possible to directly target bacterial iron homeostasis to control
airway P. aeruginosa infections via the administration of the metal gallium [211]. Gallium is taken up by
bacteria instead of iron because bacterial uptake systems cannot differentiate between them. Gallium
is then incorporated into iron-containing proteins, but, since it cannot be reduced under physiological
conditions, it impairs their normal activity and therefore bacterial survival and proliferation.
5.7. Lung Cancer
As iron is an indispensable component for cell metabolism, proliferation, and growth, it is equally
crucial for tumor metabolism, tumor proliferation, and tumor growth [171]. In fact, population-based
studies suggest that higher levels of overall body iron are linked to a higher risk of developing
cancer [172]. In particular, subjects with transferrin saturation level above 60% were reported to have
increased risk to develop lung cancer [212]. It was proposed that cancer cells reprogram their cellular
iron metabolism towards an increase in cellular iron uptake and decrease of iron export [172]. Briefly,
cancer cells increase iron uptake by increasing the expression of TfR1 and also via increased secretion
of lipocalin-2. Tumour cells expressing TfR1 were detected in 88% of patients with non-small-cell
lung cancer (NSCLC), while TfR1 was not detected in the tumor stroma [173]. Furthermore, it was
shown that the microRNA miR-20a is inversely correlated with FPN expression in NSCLC cells and
that low cellular FPN expression stimulates tumor cell proliferation and colony formation, potentially
via increased cellular iron availability [174]. In parallel, a reduction in FPN protein levels in tumor cells
might also result from increased hepcidin expression in these cells, probably acting in an autocrine
manner [172]. Together, these modifications of cellular iron homeostasis lead to an increased labile
iron pool (LIP) within cancer cells.
The role of the IRE/IRP system in regulating intracellular iron levels in tumor cells is still
incompletely understood [172]. However, it is worth mentioning that IRP2 was suggested to have
pro-oncogenic activity in lung cancers based on tumor tissue microarray analyses [175]. Lung
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adenocarcinomas, as numerous other cancers, induce tumor-associated inflammation, a mechanism
that is triggered by activating central inflammatory pathways, such as the NFκB-signaling pathway.
NFκB signaling is important for tumor cell proliferation, apoptosis, metabolism, as well as for tumor
angiogenesis and metastasis. NFκB itself can induce the HIF-signaling pathway in both, normoxic and
hypoxic conditions. Conversely, HIFs can modulate NFκB-signaling in a bidirectional manner [213].
Overall, the strong iron dependency of lung cancer offers the opportunity for treatment
interventions that target iron availability (e.g., iron chelators); however, future pre-clinical and clinical
studies are needed to address this potential treatment. In a different perspective, iron modulation in
tumor-associated macrophages (TAMs) might also emerge as a possible therapeutic target. Recent
studies indicate that the iron loading of TAMs can differentiate them towards a pro-inflammatory
phenotype and inhibit tumour growth [176,214]. Supporting this idea, the presence of iron loaded
TAMs correlates with reduced tumor size in patients with non-small cell lung cancer [176].
5.8. Other Diseases
Acute respiratory distress syndrome (ARDS) is clinically characterized by severe hypoxemia
resulting from pulmonary gas exchange failure [160]. A potential source of iron in ARDS may
derive from ‘low grade bleeding’ and hemorrhage, which might be present in certain subsets of this
heterogenous pathological lung condition [215]. Analysis of the bronchoalveolar lavage of patients
suffering from ARDS revealed the presence of higher levels of iron and iron-related proteins, such as
ferritin, lactoferrin, and transferrin, likely reflect disturbances in lung iron homeostasis [9]. Similarly,
patients with pulmonary alveolar proteinosis (PAP), a disease defined by severe accumulation of
surfactant in the airspaces and hypoxemia [177], also present higher concentrations of iron, ferritin,
transferrin, and lactoferrin in the bronchoalveolar lavage [178]. Finally, patients with idiopathic
pulmonary fibrosis (IPF), a restrictive lung disease with a prominent gas diffusion limitation [169], have
a higher frequency of HFE allelic variants associated with the iron overload disease hemochromatosis,
when compared to healthy controls [170]. Hemosiderin accumulation in alveolar macrophages was
increased in these patients. Whether these alterations in pulmonary iron homeostasis contribute to the
pathology of these diseases is still unknown.
Pulmonary dysfunction, in particular restrictive lung disease, is frequently observed in patients
with thalassemia major (TM), a disease characterized by severe iron accumulation [186–189]. It has
been speculated that abnormal lung function in those patients might be a consequence of chronic iron
overload [189]. Supporting this hypothesis, a restrictive pattern was observed in a mouse model of iron
overload, caused by a mutation in FPN that confers resistance to hepcidin binding [56]. In addition to
thalassemia, other hemolytic diseases, such as sickle cell disease, are also associated with increased
susceptibility to pulmonary diseases and abnormal lung function [216–218]. However, future studies
are needed to fully understand the impact of iron overload in lung function in humans and whether
additional factors such as hemoglobin and heme release in these hemoglobinopathies contribute for
the lung disorders observed in these patients.
6. Therapeutic Potential of Iron Modulation
The profound numbers of lung diseases associated with disrupted iron homeostasis offer a
great potential for the therapeutic careful use of iron modulators. Before corrective interventions
can be applied in patients, we require a better knowledge of iron’s role in pulmonary disease and
markers to properly evaluate the systemic and pulmonary iron status. Currently, dietary interventions,
phlebotomy, blood and iron infusions, as well as iron chelator treatment, are used to correct systemic
disturbances of iron homeostasis. For example, blood infusions and iron-chelation therapy are standard
in the treatment of hemolytic anemias. In PH patients, the therapeutic correction of the frequently
observed iron deficiency may ameliorate the disease outcome and clinical trials are ongoing to further
investigate this potential [180]. The first trial results seem to support this concept, however so far only
for the idiopathic PH-subtype [185].
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Future approaches will directly target regulatory molecules of iron metabolism by applying small
agonistic/antagonistic molecules. It is tempting to speculate that such molecules might be applied by
inhalation. For example, hepcidin as the major regulator of iron metabolism and its receptor FPN are
promising targets for future drug development [219]. Indeed, hepcidin agonists are currently under
development to treat iron overload diseases such as hereditary hemochromatosis. On the other hand,
hepcidin antagonists are developed to treat inflammation-induced anemias.
Moreover, diseases such as COPD that are characterized by systemic iron deficiency and lung iron
accumulation would benefit from a more specific strategy. For example, inhalation of chelators
(or iron sources, in case of lung iron deficiency) would have the potential to directly modulate
pulmonary iron homeostasis while hopefully having no or only a mild effect on systemic iron
homeostasis. Apart from direct targeting of regulators of iron metabolism, indirect targeting of
signaling pathways, such as the HIFs, may be an option [220,221]. In summary, therapeutic possibilities
to control iron metabolism are widespread, and the pros and cons of these novel therapeutic approaches
need to be carefully evaluated.
7. Conclusion and Outlook
In healthy conditions, pulmonary iron homeostasis is tightly controlled to maintain proper
lung function. In environmental (e.g., high-altitude exposure) and behavioral (e.g., exercise) stress
conditions it requires adaptation. Importantly, numerous acute and chronic respiratory diseases are
associated with disrupted iron homeostasis in the lungs. The close cellular interaction between iron
regulatory pathways via IREs/IRPs or hepcidin/ferroportin and the oxygen sensing pathway via
HIFs seems to be critical for healthy adaption but also for pathologic maladaptation within the lungs.
Enormous progress has been made in our molecular understanding of these pathways and their
suppression and/or enhancement. However, this knowledge currently needs to be applied to the lung.
An improved understanding of iron trafficking and storage in the lung and its role in lung disease
onset and progression will improve interventional modification of iron homeostasis within the lungs
via iron-modulators.
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